OBJECTIVE: The objective was to examine the effect of repeated applications of coupled plasmafiltration-adsorption on the hemodynamic response in septic shock patients hospitalized in intensive care units (ICUs). DESIGN: Prospective, intention-to-treat. SETTING: General ICU of a tertiary care, non-teaching, 400-bed, city hospital. PATIENTS AND PARTICIPANTS: Twelve consecutive mechanically ventilated septic shock patients, with or without concomitant acute renal failure (ARF). INTERVENTION: A median of 10 consecutive sessions (prescribed treatment time: 10 h/session; delivered duration: 8.43+/-1.37 h/min) of coupled plasmafiltration-adsorption for each patient. MEASUREMENTS AND RESULTS: Mean arterial pressure (77.2+/-12.5 [CI 95%; 74.5-79.8] vs. 83.3+/-14.1 [CI 95%; 80.3-86.3] mm Hg; [ p<0.001]), cardiac index (4.03+/-0.89 [CI 95%; 3.83-4.22] vs. 3.46+/-0.82 [CI 95%; 3.28-3.64] L/m(2)/min; [ p<0.001]), systemic vascular resistance index (1,388+/-496 [CI 95%; 1,278-1,497] vs. 1,753+/-516 [CI 95%; 1,639-1,867] dynes x s/cm(5); [ p<0.001]), PO2/FIO2 ratio (204+/-87 [CI 95%; 185-223] vs. 238+/-82 [CI 95%; 220-256]; [ p<0.001]), significantly improved during 100 global treatments (pre- vs. post-treatment values). Intra-thoracic blood volume and extra-vascular lung water did not change across treatments. Vasopressor requirement was reduced: norepinephrine decrease from an infusion rate of 0.13+/-0.07 (CI 95%; 0.06-0.16) to 0 gamma/kg/min after a mean of 5.3+/-2.7 sessions. C reactive protein (CRP) significantly decreased (from 29.3+/-7.3 vs. 7.9+/-4.8; p<0.0001) during treatment. Survival was 90% at day 28 and 70% at day 90. CONCLUSION: Coupled plasmafiltration-adsorption was a feasible and safe extracorporeal treatment and exerted a remarkable improvement in the hemodynamics, the pulmonary function, and the outcome in septic shock patients with or without concomitant ARF.
OBJECTIVE: The objective was to examine the effect of repeated applications of coupled plasmafiltration-adsorption on the hemodynamic response in septic shockpatients hospitalized in intensive care units (ICUs). DESIGN: Prospective, intention-to-treat. SETTING: General ICU of a tertiary care, non-teaching, 400-bed, city hospital. PATIENTS AND PARTICIPANTS: Twelve consecutive mechanically ventilated septic shockpatients, with or without concomitant acute renal failure (ARF). INTERVENTION: A median of 10 consecutive sessions (prescribed treatment time: 10 h/session; delivered duration: 8.43+/-1.37 h/min) of coupled plasmafiltration-adsorption for each patient. MEASUREMENTS AND RESULTS: Mean arterial pressure (77.2+/-12.5 [CI 95%; 74.5-79.8] vs. 83.3+/-14.1 [CI 95%; 80.3-86.3] mm Hg; [ p<0.001]), cardiac index (4.03+/-0.89 [CI 95%; 3.83-4.22] vs. 3.46+/-0.82 [CI 95%; 3.28-3.64] L/m(2)/min; [ p<0.001]), systemic vascular resistance index (1,388+/-496 [CI 95%; 1,278-1,497] vs. 1,753+/-516 [CI 95%; 1,639-1,867] dynes x s/cm(5); [ p<0.001]), PO2/FIO2 ratio (204+/-87 [CI 95%; 185-223] vs. 238+/-82 [CI 95%; 220-256]; [ p<0.001]), significantly improved during 100 global treatments (pre- vs. post-treatment values). Intra-thoracic blood volume and extra-vascular lung water did not change across treatments. Vasopressor requirement was reduced: norepinephrine decrease from an infusion rate of 0.13+/-0.07 (CI 95%; 0.06-0.16) to 0 gamma/kg/min after a mean of 5.3+/-2.7 sessions. C reactive protein (CRP) significantly decreased (from 29.3+/-7.3 vs. 7.9+/-4.8; p<0.0001) during treatment. Survival was 90% at day 28 and 70% at day 90. CONCLUSION: Coupled plasmafiltration-adsorption was a feasible and safe extracorporeal treatment and exerted a remarkable improvement in the hemodynamics, the pulmonary function, and the outcome in septic shockpatients with or without concomitant ARF.
Authors: E F Yekebas; C F Eisenberger; H Ohnesorge; A Saalmüller; H A Elsner; M Engelhardt; A Gillesen; J Meins; M The; T Strate; C Busch; W T Knoefel; C Bloechle; J R Izbicki Journal: Crit Care Med Date: 2001-07 Impact factor: 7.598
Authors: C Tetta; J M Cavaillon; M Schulze; C Ronco; P M Ghezzi; G Camussi; A M Serra; F Curti; G Lonnemann Journal: Nephrol Dial Transplant Date: 1998-06 Impact factor: 5.992
Authors: Claudio Ronco; Alessandra Brendolan; Gerhard Lonnemann; Rinaldo Bellomo; Pasquale Piccinni; Antonio Digito; Maurizio Dan; Marco Irone; Giuseppe La Greca; Paola Inguaggiato; Umberto Maggiore; Concetta De Nitti; Mary Lou Wratten; Zaccaria Ricci; Ciro Tetta Journal: Crit Care Med Date: 2002-06 Impact factor: 7.598
Authors: Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoît Vallet Journal: Intensive Care Med Date: 2004-05-15 Impact factor: 17.440
Authors: Yu Kawai; Timothy T Cornell; Elaine G Cooley; Craig N Beckman; Paula K Baldridge; Theresa A Mottes; Kera E Luckritz; Kathryn S Plomaritas; J Michael Meade; Folafoluwa O Odetola; Yong Y Han; Neal B Blatt; Gail M Annich Journal: Pediatr Crit Care Med Date: 2015-05 Impact factor: 3.624
Authors: Rodrigo Cornejo; Patricio Downey; Ricardo Castro; Carlos Romero; Tomas Regueira; Jorge Vega; Luis Castillo; Max Andresen; Alberto Dougnac; Guillermo Bugedo; Glenn Hernandez Journal: Intensive Care Med Date: 2006-03-21 Impact factor: 17.440
Authors: Elena Garbero; Sergio Livigni; Fiorenza Ferrari; Stefano Finazzi; Martin Langer; Paolo Malacarne; Manlio Cosimo Claudio Meca; Sabino Mosca; Carlo Olivieri; Marco Pozzato; Carlotta Rossi; Mario Tavola; Marina Terzitta; Bruno Viaggi; Guido Bertolini Journal: Intensive Care Med Date: 2021-10-03 Impact factor: 17.440